Assembly Biosciences, Inc. (NASDAQ:ASMB – Free Report) – Investment analysts at HC Wainwright lowered their Q4 2027 EPS estimates for Assembly Biosciences in a research note issued on Tuesday, August 18th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings of $1.63 per share for the quarter, down from their previous forecast of $1.66. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is $1.90 per share.
Several other equities analysts have also recently weighed in on ASMB. Mizuho set a $45.00 price objective on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research note on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Guggenheim reissued a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a report on Thursday, May 28th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Assembly Biosciences currently has an average rating of “Moderate Buy” and an average target price of $44.00.
Assembly Biosciences Stock Performance
Assembly Biosciences stock opened at $32.13 on Wednesday. The stock has a market cap of $510.64 million, a PE ratio of 31.50 and a beta of 1.10. The stock has a fifty day moving average of $26.43 and a 200 day moving average of $27.44. Assembly Biosciences has a one year low of $20.23 and a one year high of $39.71.
Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.52. The business had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Stempoint Capital LP grew its stake in shares of Assembly Biosciences by 18.3% during the first quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock worth $5,146,000 after acquiring an additional 28,707 shares during the last quarter. Eversept Partners LP purchased a new position in shares of Assembly Biosciences in the 4th quarter valued at approximately $5,431,000. 683 Capital Management LLC acquired a new stake in Assembly Biosciences in the 4th quarter worth approximately $948,000. Bank of America Corp DE boosted its stake in Assembly Biosciences by 113.3% in the 1st quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock worth $303,000 after purchasing an additional 5,792 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Assembly Biosciences by 69.4% during the 1st quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 6,411 shares during the last quarter. 19.92% of the stock is currently owned by hedge funds and other institutional investors.
About Assembly Biosciences
Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.
The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.
Featured Articles
- Five stocks we like better than Assembly Biosciences
- Amazon Plugs $18B Into the Southern Power Grid
- Speed Sells: Cerebras Cracks the Silicon Ceiling
- Amid Legal Risks, This Company Is Still Rated a Buy
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
